Dr. Hassan Jaafar Consultant Medical Oncology

Research & Publications

• Bilateral breast involvement in acute myelogenous leukemia, Mammographic and ultrasound findings. The European Radiology 2000; 10 (6):1031
• Recurrence of thrombocytopenia in previously diagnosed thrombotic thrombocytopenia purpura (TTP) does not always mean TTP recurrence. Annals Saudi med. 2003 may-jul;23(3-4):228-9.
• Strongyloidiasis hyper-infection causing life-threatening gastrointestinal bleeding. World J Gastroenterol. 2006 Oct 21;12(39):6401-4.
• Metastatic Castrate Resistant Prostate Cancer: Current Strategies of Management in the Middle East. Critical Reviews in Oncology/Hematology" Journal 2013 Nov 8.pii: s1040-8428(13)00229-1
• Impact of Oncotype DX Testing on Adjuvant Treatment Decisions in Patients with Early Breast Cancer: A Single-Center Study in the United Arab Emirates Asia Pac J Clin Oncol. 2014 Sep 22. Doi: 10.1111/ajco.12259.
• Enviroximes with endocrine therapy as a treatment option in ER + MBC failing at least one line of endocrine therapy: a single institute experience, Pan Arab Journal of oncology vol 7; issue 2, June 2014.
• A multicenter prospective phase II trial of neoadjuvant eirenicon, cyclophosphamide, and five‑fluorouracil (FEC100) followed by cisplatin–docetaxel with or without trastuzumab in locally advanced breast cancer. Cancer Chemotherapy Pharmocol DOI 10.1007/s00280-015-2906-5
• Epidemiology of breast cancer in the United Arab Emirates – a multi-Ethnic population Emirates Oncology Journal EOJ 2 November 2015
• Patterns of epidermal growth factor receptor mutation in non-small-cell lung cancers in the Gulf region. Molecular and Clinical Oncology 3: 1371-1374, 2015
• Supportive care needs of multicultural patients with cancer in the United Arab Emirates E-cancer medical science. 2018 May 29; 12:838 Doi: 10.3332/ecancer.2018.838.eCollection 2018.
• The study of druggable targets in no squamous non-small-cell lung cancer in the Middle East and North Africa Journal of Immunotherapy and Precision Oncology 2 (1), 4-7
• Patterns of diagnostic procedures for lung cancer pathology in the Middle East and North Africa Journal of thoracic disease 11 (12), 5162
• The State of Cancer Care in the United Arab Emirates in 2020: Challenges and Recommendations, A report by the United Arab Emirates Oncology Task Force. The Gulf journal of oncology 1 (32), 71-87
• Comprehensive review into the challenges of gastrointestinal tumors in the Gulf and Levant countries RTGI Group World journal of clinical cases 8 (3), 487
• 151P Prevalence of Anaplastic Lymphoma Kinase (ALK)+ Non-Small Cell Lung Cancer (NSCLC) in the Middle East and North Africa (MENA), Annals of Oncology 31, S299
• Epidermal growth factor receptor (EGFR) positive non-small-cell lung carcinoma (NSCLC) patients in the Gulf region: current status, challenges, and call for action Journal of Cancer Prevention & Current Research 11 (Issue 5 - 2020), (5):130‒134
• Management guidelines for stage III non-small cell lung cancer, Critical Reviews in Oncology/Hematology 157, 103144
• Early Diagnosis of Lung Cancer in the United Arab Emirates: Challenges and Strategic Recommendations, Clin. Pract. 2021, 11, 671–678.
• Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer in the Middle East and North Africa, JCO Global Oncol 7:1556-1563.2021 by American Society of Clinical Oncology
• ZO-FAST international study on adjuvant hormonal treatment (letrozole) in combination with Zometa.co-investigator
• A Phase III prospective, two-cohort non-randomized, multi-center, multinational, open label study to assess the safety and assisted and self -administered subcutaneous Trastuzumab as adjuvant therapy in patients with operable Her2 positive Early Breast Cancer, co-investigator
• An open-label, randomized, Phase III b trial evaluating the efficacy and safety of standard of care +/- continuous bevacizumab treatment beyond progression of disease (PD) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after first (1st)-line treatment with Bevacizumab plus a platinum doublet-containing chemotherapy. Primary investigator in
• MO28047 a Multicenter, Open-Label, Single-Arm Study of Pertuzumab in Combination with Trastuzumab and A Taxane in First Line Treatment of Patients with Her2- Positive advanced (Metastatic or Locally Recurrent) Breast Cancer, Primary
• A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer, Co-investigator
• A phase 3 randomized double-blind, placebo-controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment, Primary investigator
• PIK3CA Registry A descriptive study of PIK3CA mutations in patients with HR+/HER2- advanced breast cancer Protocol No. CBYL719C2401 Non-Interventional Studies Original protocol dated 30-Sep-2019, Primary investigator

Education & Training

• MBChB
• Fellowship (Hematology, Oncology)
• Arab Board in Internal Medicine

Membership

• ESMO European Society of Medical Oncology
• ASCO American Society of Medical Oncology
• Member of the Scientific and Education Committee of the Arab Collaborative Hematology and Oncology Group (ACHOG) 2012
• MENA NCCN HCC Group
• Scientific Committee for the Emirates Oncology Conference - 2012-2016
• MENA NCCN Lung Cancer Group
• GIST Working Group
• Africa Middle East Cancer Research Intergroup (AMCI)
• UAE Oncology and Radiation Therapy Association
• Lebanese Hematology Oncology Association